Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10875)
  2. Meeting Abstract (9464)
  3. Review (551)
  4. Book Section (417)
  5. Editorial (334)
  6. Guidelines (157)
  7. Correspondence (116)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22139)
  2. GSK Faculty (5904)
  3. Genitourinary Oncology Service (5632)
  4. Survivorship Research (5206)
  5. Gastrointestinal Oncology Service (4671)
  6. Breast Medicine Service (4121)

More Groups

People
  1. Robert Motzer (1246)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (870)
  6. Leonard Saltz (791)

More People

Years
  1. 2025 (540)
  2. 2024 (1386)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5253)
  2. Annals of Oncology (1295)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (772)
  5. Journal of Thoracic Oncology (531)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5544)
  2. Elsevier Inc. (2654)
  3. American Association for Cancer Research (2322)
  4. Oxford University Press (1812)
  5. Nature Publishing Group (1030)
  6. Springer (979)

More Publishers

Results (22161)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163)
    Meeting Abstract

    Saba, N. F.; Flamand, Y.; Lin, D. T.; Chung, C. H.; McDonald, M. W.; Flampouri, S.; Khan, S. A.; Snyderman, C. H.; Hanna, E.; El-Sayed, Y. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Global, phase Ib dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced (a) endometrial cancer (EC) that progressed on platinum-based chemotherapy (CTx) and an anti-PD-(L)1 immunotherapy (IO)
    Meeting Abstract

    Lee, J. Y.; Hasegawa, K.; Kim, B. G.; Corr, B. R.; Kondo, S.; Suzuki, S.; Yunokawa, M.; Miller, D. S.; Tamai, T.; Dutta, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)
    Meeting Abstract

    Lee, J. M.; MacLaughlan, S.; Matei, D.; Song, M.; Brubaker, L.; Rimmel, B.; Eskander, R. N.; Kyi, C.; Williams, H.; Duska, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
    Meeting Abstract

    Friedman, C.; De Burgh Williams, A.; Lopez, J. S.; Ouali, K.; Middleton, M. R.; Thistlethwaite, F.; Hamid, O.; Izar, B.; Moreno Garcia, V.; Johnson, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
    Meeting Abstract

    Schram, A. M.; Lopes, G.; El-Khoueiry, A. B.; Fontana, E.; Karasic, T. B.; Kummar, S.; Lorusso, P.; Gregorc, V.; Millward, M.; Aix, S. P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study
    Meeting Abstract

    Oaknin, A.; Ang, J. E.; Rha, S. Y.; Yonemori, K.; Kristeleit, R.; Lin, C. C.; Satoh, T.; Garcia, P. E.; Sendur, M. A. N.; Rodríguez, L. M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
    Meeting Abstract

    Danska-Bidzinska, A.; Makker, V.; Salutari, V.; Ayhan, A.; Romero, I.; Levy, T.; McCormack, M.; Baurain, J. F.; Mach, P.; Cadoo, K. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    Meeting Abstract

    Twelves, C. J.; Banerji, U.; Tap, W. D.; Cook, N.; Evans, T. R. J.; Plummer, R.; Anthoney, A.; Plummer, C.; Dawson, R.; Loadman, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
    Meeting Abstract

    Carneiro, B. A.; Rosen, E.; Fontana, E.; Lee, E. K.; Mettu, N. B.; Lheureux, S.; Plummer, R.; Silverman, I. M.; Schonhoft, J. D.; Yang, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save